Category Archives: Transhuman News

When Queen Elizabeth was crowned in 1953, she promised to rule for her whole life.

It was a commitment that never waivered and saw her on the throne for more than 70 years, over which time the world changed significantly.

During her reign, the Queen saw some of the most groundbreaking moments in human history within her seven decades of service; from wars and a pandemic, to technological developments and scientific breakthroughs.

Here, we breakdown some of the most significant events that Queen Elizabeth II witnessed during her legendary time as our monarch.

There were an abundance of scientific breakthroughs during the Queens service, and in just her second year, scientists Francis Crick and James Watson published an article that claimed they had discovered what they called the secret of life.

From the University of Cambridge, the pair along with other researchers worked together to identify the now famous double helix structure aka the deoxyribonucleic molecule, also known as DNA.

This gave rise to modern molecular biology, and helped to produce new and powerful scientific techniques, specifically DNA research, genetic engineering, rapid gene sequencing, and the mapping of the human genome.

Major advances in science, including genetic fingerprinting and modern forensics, owe thanks to this discovery.

British Crick was later awarded the Queens Medal, for his contribution to science.

Shortly after, came the first organ transplant, a huge moment in medical history. The first successful operation a kidney transplant was performed by Dr Joseph Murray in Boston, Massachusetts.

The technique has since saved over 400,000 lives worldwide, with more than 3,000 kidney transplants are now carried out in the UK each year.

During the 70 years of The Queens reign, the world of highways and transportation changed significantly, with cars becoming accessible to the majority of the British population. Alongside this, the road network grew and motorways came into being.

The M6, now Britains longest motorway, was first opened in December of 1958, originally an eight mile section of road, acting as a high speed bypass around the town of Preston, Lancashire.

At the point of its inception, it had just two lanes in each direction, no safety barrier in the central reservation and no other technology. Prime Minister Harold Macmillan oversaw theopening, making the beginning of road travel in the UK more accessible than it had ever been before.

The Queen has been witness to many huge moments for womens reproductive rights and the contraceptive pill is an important one.

Considered one of the most significant medical advances of the 20th century, the contraceptive pill a combination of the hormones oestrogen and progestin was developed in the US in the 1950s by the American biologist Dr Gregory Pincus. It was later released in 1960, and within two years it was being used by 1.2million women.

The pill was introduced in the UK the following year, but initially was only available for married women. However, this changed in 1967 and the pill is now taken by over 3.1million women in the UK.

As later dramatised in Season Two of The Crown, the Queen first met President Kennedy and First Lady Jacqueline Kennedy at a reception hosted at Buckingham Palace in June 1961.

In an event that shook the world, President Kennedy was assassinated in Dallas, Texas, in 1963.

The Queen sent condolences and later invited Jacqueline Kennedy to Britain for the unveiling of the British national JFK memorial in Runnymede.

Although the Queen may have been more associated with sports like horse racing and polo, one of the most iconic photographs in British sporting history showed HRH, wearing a mustard coat and hat and long white gloves, shaking the hand of Sir Bobby Moore the England captain who led the team to victory in the 1966 World Cup.

The four-nil victory over West Germany on 30 July 1966 has still never been beaten, or equalled.

Last year, ahead of the England teams Euros final, the Queen released a statement, wishing them good luck ahead of their appearance at Wembley and reflecting on the importance of that landmark victory.

She said: Fifty-five years ago I was fortunate to present the World Cup to Bobby Moore and saw what it meant to the players, management and support staff to reach and win the final of a major international football tournament.

In 1967, the British parliament passed the Sexual Offences Act, legalising homosexual acts if they were consensual, in private, and between individuals who were at least 21 years old in England and Wales.

It was considered a landmark event for gay rights although a far cry from equality and liberation. Scotland didnt follow suit until 1980 and Northern Ireland until 1982.

It wasnt until 2004, that the Civil Partnership Act allowed same-sex couples to legally enter into same-sex unions, and it would be another 10 years before same-sex marriage was legalised in Scotland, England and Wales.

In another landmark event, the 1967 the Abortion Act was passed, which legalised abortion on certain grounds by registered practitioners.

The Queen gave her royal assent to both laws.

In 1969, NASA astronaut and aeronautical engineer Neil Armstrong became the first ever man to walk on the moon, duringApollo 11. Armstrong also flew on NASAs Gemini 8 mission in 1966.

For obvious reasons, this was a groundbreaking moment for humanity a giant leap for mankind, you might even say.

After his mission, the Queen met with Armstrong and his wife, who traveled to Buckingham Palace, as part of a world tour to meet global leaders and mark their successful mission.

The first mobile phone call was made on April 3, 1973, by Motorola employee Martin Cooper.

Using a prototype of what would become the Motorola DynaTAC 8000x, Cooper reportedly stood near a 900 MHz base station on Sixth Avenue, between 53rd and 54th Streets, in New York City and placed a call to New Jersey.

The mobile phone would go on to change the world as we know it, particularly with the introduction of the smartphone the first of which, the IBM Simon and Nokia Communicator 9000, were released in 1994 and 1996 respectively

The Queen reportedly used a Samsung featuring anti-hacker encryption by MI6. According to royal commentator, Jonathan Sacerdoti, she would mainly speak on her mobile phone to two people her daughter, Princess Anne and her racing manager, John Warren.

A year after the Queen celebrated her Silver Jubilee, following 25 years on the throne, a new groundbreaking reproductive moment was recorded; and on July 25 1978, the worlds first IVF baby was born.

Louise Brown was born at Royal Oldham Hospital, Lancashire, after the so-called test tube procedure was developed by English physiologist Robert Edwards, in collaboration with two other scientists.

In 2010, Edwards won the Nobel Prize in Physiology or Medicine, and a year later he was knighted by the Queen.

Margaret Thatcher was Britains first ever female prime minister, and served three consecutive terms in office, from 1979-1990.

During the period of Thatcherism in the 1980s, the Queen met with the prime minister weekly. They were, however, said to have a complicated relationship.

The Queen reportedly disagreed with some of Thatchers policies, including her refusal to impose sanctions on apartheid South Africa, according to a 1986 report in the Sunday Times.

But they did work together for over a decade, with the Queen later awarding Thatcher the prestigious Order of Merit.

Queen Elizabeth has been head of state during a time of profound technological advancement. And theres not much that has changed the state of the world more than the advent of the Internet.

No one person invented the Internet it occurred over a number of years, developed by a variety of scientists and engineers who initially brought their research together to create what was known as the ARPANET, the precursor to the World Wide Web.

And the Queen was more tech-enthusiastic than you might imagine. In fact, in 1976 she became the first monarch and one of the first ever people to ever send an email, during the early development stages of ARPANET, when visiting the Royal Signals and Radar Establishment in Malvern.

It wasnt until 1989 that scientist Tim Berners-Lee invented the World Wide Web. In 2003, over 20 years after it was first born, nearly half of the UK residents had access to the Internet.

On November 9, 1989, the Berlin Wall dividing East Germany and West Germany was dismantled by protesters, after a five-day gathering opposing the oppressive division.

The bringing down of the wall marked the end of the Cold War, and signified the fall of the iron curtain and the dissolution of the Soviet Union.

The Queen, of course, had her own part to play in the historic moments leading up to the end of the Cold War. Years of diplomacy had been crucial as had the Queens role in warming diplomatic relations between the UK and the Soviet Union.

In fact, just seven months before the Berlin Wall started to be dismantled before it finally fell for good in 1991 The Queen had hosted Soviet leader, Mikhail Gorbachev, on a diplomatic visit to Windsor Castle.

The Queen gave her official royal assent to The Maastricht Treaty, first signed in 1992 officially establishing the European Union, that came into force in 1993.

There were originally 12 member countries, including the United Kingdom and the EU evolved out of the European Economic Community (EEC), which partly aimed to prevent conflict after World War II.

The Queen had always appeared to be pro-Europe, in an uncontentious manner, and was, of course, still head of state when the UK vote at referendum to leave its place in the EU in June 2016.

In 2018, she commented to the king and queen of the Netherlands that Britain was looking toward a new partnership with Europe and added that shared values between Britain and Europe are our greatest asset.

Dolly the Sheep was the first mammal cloned from an adult somatic cell, and a procedure that led to widespread advancement with stem cell research.

Dolly was created and lived her life at the Roslin Institute in Scotland. One of the lead researchers, Ian Wilmut, received the Order of the British Empire from the Queen in 1999, and was knighted in 2008.

The cloned mammal produced several lambs during her lifetime, and was put to sleep after contracting a progressive lung disease, said to be unrelated to her cloning.

The Good Friday Agreement was signed on April 10, 1998, and marked the end of most of the violence related to The Troubles.

Citizens of both the Republican of Ireland and Northern Ireland voted in a referendum to approve the agreement.

The day after part of the measures went into effect, in 1999, Irish President, Mary McAleese, had lunch with the Queen in Buckingham Palace.

In 1997, the Scottish population voted for devolution with 74% of votes cast in favour, and a turnout of 60%.

Previous proposals for a Scottish Parliament had fallen at a referendum in 1979, as although a majority of Scottish voters had backed the plans, the required threshold of 40% registration of voters was not met.

This marked a period of significant change for the UK and the Queen officially opened the parliament, on 1 July 1999, giving the assembly law making powers.

Elizabeth has since spoken about the deep and abiding affection she and her late husband, Prince Philip, shared for Scotland.

On the morning of 11 September 2001, 19 Al Qaeda terrorists hijacked four commercial passenger planes in the United States.

We are all familiar with what happened next it was an event that rocked the entire world.

Following the attacks, the Queen paid her own special tribute to the Americans living and working in Britain, as well as those who had been personally affected.

For the first time in its history, the military band were authorised to play the American national anthem during the Changing of the Guard at Buckingham Palace, for the gathered crowds.

On November 4, 2008, Barack Obama defeatedJohn McCain of become the 44th U.S. president, and the first African American elected to the White House, a momentous event for the US and the world.

Since the Queens passing, the Obamas have made a heartfelt tribute, stating that they were grateful to witness her reign and dedicated leadership.

The former president said: Michelle and I were lucky enough to come to know Her Majesty, and she meant a great deal to us, adding that she welcomed us to the world stage with open arms and extraordinary generosity.

The worlds attention was focused on Britain in 2012 with the Queens Diamond Jubilee taking place that summer, as well as the London Olympics which the UK was hosting for the third time.

The Queens appeared in a video played at the Games opening ceremony with co-star James Bond, which saw her skydiving into the Olympic Stadium before he declared the event to be open.

In 2016, citizens of the United Kingdom voted to take their nation out of the European Union.

The referendum saw David Cameron resign as prime minister, and Theresa May take over the position.

After years of negotiations, the UK finally withdrew, on January 21, 2020.

The Queen gave her royal assent to the bill that triggered the U.K.s withdrawal a monumental moment in the countrys history.

Nobody could have foreseen the chaos that the outbreak of Covid-19 in the UK would bring and the knock on impact of it dominated much of the Queens final years, personally and professionally.

The lockdowns announced as a result saw the Queen broadcast only her fifth message to the nation, in her 70 year reign.

Other than her Christmas speech, she has only given a speech of this gravity during occasions including the beginning of the first Gulf War and the death of Princess Diana.

During her speech, the Queen reassured the nation with the heartfelt words: We should take comfort that, while we may have more still to endure, better days will return: we will be with our friends again; we will be with our families again; we will meet again.

MORE : Tiny portions and ice-cold drinks: Royal butler reveals special memories of time with the Queen

MORE : King Charles IIIs historic proclamation speech in full

MORE : Princess Beatrice will take on new role following death of the Queen

Read the original:
24 groundbreaking events that happened during the Queen's reign - Metro.co.uk

A newly developed antibody that increases the activation of TREM2a receptor on microgliareduces amyloid burden and alleviates cognitive decline in mice exhibiting Alzheimers disease (AD) pathology. These findings indicate that the antibody, Ab18 TVD-Ig/aTfR, may have promise as a treatment for the disease.

The work was led by Zhiqiang An, PhD, professor at McGovern Medical School at the University of Texas Health Science Center at Houston, and Ningyan Zhang, PhD, professor at the Texas Therapeutics Institute at the Brown Foundation Institute of Molecular Medicine. Their team published their work in Science Translational Medicine in an article entitled, A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimers disease.

Alzheimers disease, which is characterized by the loss of memory and thinking skills, affects more than 10% of the elderly population. Amyloid-beta oligomers and plaques in the parenchyma of the brain are pathological hallmarks of the disease.

Microglia in the brain play crucial roles in amyloid-beta pathology. TREM2, a receptor expressed by microglia, regulates the migration of microglia toward and phagocytosis of amyloid-beta oligomers and plaques.

The research team postulated that increasing TREM2 activation on the microglia would enhance these effects. They identified an antibody that could accomplish this task and then engineered it to enhance its potency and brain penetrance.

Here, we identified a TREM2 agonist monoclonal Ab (Ab18) by panning a phage-displayed single-chain variable fragment Ab library, they wrote.

By engineering the bivalent immunoglobulin G1 (IgG1) to tetra-variable domain immunoglobulin (TVD-Ig), we further increased the TREM2 activation by 100-fold, they continued. An engineered bispecific Ab targeting TREM2 and transferrin receptor (TfR; Ab18 TVD-Ig/aTfR) improved Ab brain entry by more than 10-fold with a broad parenchyma distribution.

An attributed their success to the resources and expertise of his collaborators. One of the major areas of focus at the Texas Therapeutics Institute is developing technologies to deliver antibody-based therapies across the blood-brain barrier for potential treatment of the disease, he said.

The researchers then treated a mouse model of Alzheimers disease with the engineered antibody. Weekly treatment of 5XFAD mice (a model of AD) with Ab18 TVD-Ig/aTfR showed a considerable reduction of amyloid burden with increased microglia migration to and phagocytosis of amyloid plaques, improved synaptic and neuronal marker intensity, improved cognitive functions, reduced endogenous tau hyperphosphorylation, and decreased phosphorylated neurofilament H immunostaining, they wrote.

In sum, the results indicated that antibody-mediated TREM2-targeting therapies might be effective for treating Alzheimers disease, but the researchers say that more work is needed before they can be brought to the clinic.

[W]e demonstrated the feasibility of engineering multivalent TREM2 agonistic antibodies coupled with TfR-mediated brain delivery to enhance microglia functions and reduce amyloid pathology in vitro and in vivo, said Zhang. This antibody engineering approach enables the development of effective TREM2-targeting therapies for AD.

Read the original here:
Engineered Antibody Shows Therapeutic Effects in Mouse Model of Alzheimer's Disease - Genetic Engineering & Biotechnology News

Mixing superheroes and science is always a great recipe. The Imperfects is a show that has its heart in the right place, and one can tell they tried. Seriously, this show has everything, right from great world-building to detailed backstories and characters with complete personalities. It is also a show that really respects and encourages the audiences intelligence. But at the end of it, it just lacks grit and that zing, which is necessary for something to be interesting. The Imperfects Season 1 follows three people: Abbi, Tilda, and Juan, who set out to find the cure for their supernatural abilities, which they gained due to an experimental program in their childhood. Let us take a look at how this unfolds.

Spoilers Ahead

Lets start with the origin of our protagonists superpowers. In the words of Dr. Alex Sarkov, the interaction between the human genome and environmental factors is leading to Acute Genetic Decay Syndrome, aka AGDC. It was first discovered by Dr. Sydney Burke and later proved by him. To combat that, the test subjects are injected with artificial stem cells, which basically edit the damage caused by AGDS, and the side effects of that are superpowers.The projected reason for this is that human evolution has not adapted to climate change at the rate it should have because the change itself has been accelerated due to the industrialization of the last two centuries. The rate of progress cannot be reversed or stalled, even at risk to life. To protect humans from themselves, Sarkov must continue with his experiments.

In the present day, Tilda is the lead singer of a music band. Her superpower is being able to hear every sound from miles away and having a voice that can break things. Abbi is a top-ranking student who is on the verge of getting into Oxford. She can emit pheromones that cause anyone who smells them to be hopelessly attracted to her. Finally, Juan is a comic book artist who can turn into a werewolf. His girlfriend, Darcy, who later discovers this about him, apparently has a monster fetish, which makes for one of the better jokes of that episode. The three of them have been taking pills for years to subdue these effects, but when they run out of them and new ones arent coming, they show up at Sarkovs clinic, where they meet Dr. Burke. She tells them that the pills are not going to be of any use to them and that they must find a cure. This is the beginning of their mission to find Sarkov, who has gone missing.

On their quest to find him, they meet other test subjects. One of them is Doug, who heals at a rapid rate and is pretty much indestructible. But the pain of every injury he has ever had stays with him forever. He tells the group that they will find everything they want in the scientists lab. Another person they meet is a guy whose skin is impenetrable. With him, The Imperfects Season 1 explores the possible issue of self-esteem that superheroes deal with. Thinking about it, thats why we love the heroesbecause they save the world by fixing everything that is wrong with it. Without their powers, they would be just another person that nobody would give a second look to. It reminds us of when Tony Stark says that if you are nothing without your suit, you shouldnt have it. Everyone wants power, and everyone wants to be special. Thats why when these three set out to build a normal life for themselves, there are people who want to use them for their own benefit. One of them is a team of bio-hackers, as they like to call themselves. They had initially run into Maxwell Schifrin, one of the test subjects, who had started developing gills and told them about the experiments. They lure our group into captivity to conduct further tests on them, but the three manage to escape, killing them in the process, albeit not completely intentionally. But the very next problem they encounter is far more serious and difficult to tackleit is the government itself, which is hot on their tracks.

Abbi, Tilda, and Juan manage to find Sarkov. Turns out, he was just trying to find a cure for the situation. A number of other events take place as well. It turns out that Dr. Burke has an alter ego called Isabel Finch. Its a very Jekyll and Hyde situation that reveals that even Burke has AGDS. Her attempts to treat herself have resulted in the creation of Isabel Finch and when she transforms, even her physical appearance changes. Finch hates everyone in Burkes field and is on a mission to kill them, one by one. There is also some personal drama, mostly to involve the audience in the protagonists lives. Like the constant flirtation between Juan and Tilda, the relationship between Abbi and Hannah and Tildas friends pushes her out of the band. The biggest shocker for her is probably when her boyfriend is killed by an attack from a rogue scientist who has transformed into the imperfects. Coming back to the aforementioned governments interest in the group, a secret organization called Flux is monitoring their activities and wants to find them for their own purposes.

It is no secret that Sarkov conducts the entire operation with an utter disregard for human life yet carries a sense of the savior complex with him. Through the flashbacks, we understand that he is a bit of a mad genius whose parents died when he was 2 years old, and he has grown up at the university since he was 5. Sydney has been his only friend, and science has been his sole purpose. And even she has a sketchy moral compass. After the failure of his idea to use nanobots due to Tilda, he discovers that there is another way that the cure can be spread. Finch knows it, and she agrees to let Sarkov have it if he can successfully subdue Sydney. Reckless of others as always, he agrees, and Juan is his test subject. He decides to see if he can turn him into a Chupacabra permanently and injects him with the cure when he is in his transformed state, strapped to the bed. But as fate would have it, this is the way to the cure, and Juan looks healed. Tilda and Abbi, who have reached there, dont waste time and immediately inject Finch, bringing Sydney back to the surface. Abbi goes on to take the cure, and so do the others in the wellness program, except Tilda. She keeps hers as a way of helping others like her.

As for Sarkov, his end in the current storyline is a little less than graceful. Under the influence of Abbis pheromones, he confessed that he had received his funding from Helix, which turned out to be a shell company. Also, Dominique Crain had underwritten multiple rogue scientists, which kept Flux going and created a lot of monsters. This brings us to the last 15 minutes of the finale that set the stage for the next season. Sarkov is taken into custody by Flux, and they even hire Sydney for the next stage of their renewed operations. But they still need Sarkov for his genius. Sydney negotiates with him to help set things straight in exchange for immunity for his actions. During this, Sarkov realizes that Finch is in control of Burkes body. When he is being taken away, she gets a call from Dr. Halenbeck, and this is the biggest surprise of all, as well as the possible explanation of Sarkovs God complex. He is a genetically engineered person who was created for the sole purpose of science. But he had turned out to be surprisingly human and unruly, with ambitions of his own, which had disrupted his creators plans entirely. Dr. Halenbeck doesnt seem to be aware that he is talking to Finch and not Sydney. She promises him that she will find a solution to the problem with the help of Sarkov. What the problem is, remains to be seen. And lets make a note of the fact that Sarkovs entire savior mentality is centered around how he doesnt mind the sacrifice of a few for the greater good. He simply wants to eradicate disease and hunger with science but disregards the importance of the role of emotional intelligence required in the process. We believe there is hope for his redemption, and we just want to see how that happens.

We saw that of our trio, Tilda was the only one who was able to master her powers. For Juan and Abbi, the cure backfires. Juan starts turning into the Chupacabra once more, and Abbi is rendered helpless by the goo that spreads to the walls and traps her inside. Everyone who has taken the cure is turning into a monster, which means that Sarkovs cure has either backfired, or was successfully weaponized by Flux. But looking at how Finch and Burke have come together to be one person, it is probably possible that the affected test subjects can lead a normal life by learning to harness their powers. This is a discussion for The Imperfects Season 2.

When it comes to the show, its premise of genetic engineering is something new and has great potential. But it just doesnt hit. It tries to be funny, but the humor is not really believable. It breaks our hearts that we are unable to like The Imperfects as much as we want to because there is a genuine attempt to make something good here. It has just not landed as well as it could have. And while all the characters were well fleshed out, only Tilda and Sarkov brought a uniqueness to them, even though the latter seemed constantly confused with his accent. We will give the second season of The Imperfects a chance, in the hopes that it will pick up the pace. The pace better be great because the second chance is purely out of respect for the attempt that was made. We are keeping our fingers crossed for whenever that happens.

The Imperfects is a 2022 Drama Action series streaming on Netflix.

More:
'The Imperfects' Ending, Explained - Do Abbi, Tilda, & Juan Find The Cure? What To Expect From Season 2? | DMT - DMT

Preventing serious negative effects

The research team then examined the ancient stool samples gathered from various locations and compared them with contemporary samples received from people with whipworms from around the world. This provided them an insight into the evolution of the worm over ten-thousands of years.

"Unsurprisingly, we can see that the whipworm appears to have spread from Africa to the rest of the world along with humans about 55,000 years ago, following the so-called 'out of Africa' hypothesis on human migration," stated Kapel.

As mentioned above, a whipworm infection can have a beneficial impact on a healthy host. When it comes to severe infections, on the other hand, it can lead to dysentery, anemia, and rectal prolapse, and in children, it can impede healthy growth.

The researchers believe that this new research could help develop new ways to prevent such effects.

The findings have been published in the journal Nature Communications.

Abstract:

The neglected tropical disease trichuriasis is caused by the whipworm Trichuris trichiura, a soil-transmitted helminth that has infected humans for millennia. Today, T. trichiura infects as many as 500 million people, predominantly in communities with poor sanitary infrastructure enabling sustained faecal-oral transmission. Using whole-genome sequencing of geographically distributed worms collected from human and other primate hosts, together with ancient samples preserved in archaeologically-defined latrines and deposits dated up to one thousand years old, we present the first population genomics study of T. trichiura. We describe the continent-scale genetic structure between whipworms infecting humans and baboons relative to those infecting other primates. Admixture and population demographic analyses support a stepwise distribution of genetic variation that is highest in Uganda, consistent with an African origin and subsequent translocation with human migration. Finally, genome-wide analyses between human samples and between human and non-human primate samples reveal local regions of genetic differentiation between geographically distinct populations. These data provide insight into zoonotic reservoirs of human-infective T. trichiura and will support future efforts toward the implementation of genomic epidemiology of this globally important helminth.

Visit link:
Ancient Viking poop helped scientists map the genetics of a 5000-year-old parasite - Interesting Engineering

Find was published in one of the world's most prestigious scientific journals

By WAM

Published: Sat 10 Sep 2022, 3:26 PM

Last updated: Sat 10 Sep 2022, 4:25 PM

A team of researchers from UAE University (UAEU) succeeded in discovering an unknown type of crustacean, "Diplostraca", of microorganisms in the animal kingdom in Arabian Peninsula within the group of common species.

The team from the university's Department of Biology at the College of Science in cooperation with several researchers and international centers in Russia,

The research was published among the most prestigious scientific journals in the world, led by Professor Waleed Hamza - from the Department of Biology at the College of Science at the UAE University, in collaboration with Professor Alex Kotov, and researcher Anna Nertina from the Severtsov Institute of Ecology and Evolution in Russia, Dr Khaled Amiri - Director of Khalifa Center for Genetic Engineering and Biotechnology, researchers from the Papanin Institute for Biology of Inland Waters, at the Russian Academy of Sciences, and a master's student from the Department of Biology, and Shamma Al Neyadi, who spent 21 days at the Russian Institute to perfect her drawings using the most advanced camera Lucida.

Professor Waleed Hamza (Principal investigator)- from the Department of Biology at UAE University, said: "I believe that the discovery of new species that grew in temporary bodies of fresh water, will open the door for many researchers to explore different environments not only in the United Arab Emirates, but in the Arabian Peninsula.

"The region still has a lot to discover, in fact, expanding our research field and cooperating with world-class institutes will positively enhance our research capabilities especially when UAE young researchers participate, which will lead to building national capacities capable of exploring the resources in their land."

He added: "The importance of this scientific discovery comes in increasing the biodiversity list of living organisms, especially in the United Arab Emirates. This increases the value of preserving wetland ecosystems as a vital resource that preserves the Earth's environment and living creatures."

Researchers have found a new species of microorganism in the deserts of the Arabian Peninsula. This discovery allows to solve some problems related to the history of these daphnids in the northern hemisphere and to follow the dispersal of these microorganisms across North Africa and the Middle East. The team studied the patterns of the distribution of biodiversity and the history of its formation in continental waters. The most scientific publications about this genus are related to the sub-genus while no similar study has been done, for microorganisms that live mainly in temporary water bodies.

Professor Waleed Hamza, pointed out, "We succeeded in reaching the identity of the organism, identified as a new species and named it "Daphnia arabica sp. nov," to refer to its presence in the Arabian Peninsula" and to distinguish it from other species, belonging to another group, which live mainly in temporary bodies of fresh water. The researchers collected a core sample of dry sediment behind the Shuwaib Dam (Al Ain City) in March 2018.

ALSO READ:

The sediment was immersed in drinking water for three weeks, the sediment-encapsulated eggs hatched, and disintegrated organisms were isolated and grown in the Marine Biology Lab at the College of Science at the United Arab Emirates University, with the help of the Khalifa Center for Genetic Engineering & Biotechnology and the Russian Academy of Sciences in Moscow. The isolated organisms deeply underwent microscopic morphometric, molecular (DNA), and further genomic and morphologic analyses using the modern "camera lucida".

Originally posted here:
UAE University researchers discover new type of freshwater crustacean - Khaleej Times

Synlogic, Inc.

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has received a milestone payment for the achievement of prespecified success criteria under the research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease (IBD).

Under the terms of the agreement, Synlogic and Roche will collaborate to develop a Synthetic Biotic addressing an undisclosed novel target in IBD. At the conclusion of the research period, Roche will have the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the program.

Learn more aboutSynlogicsprograms and pipeline by visitinghttps://www.synlogictx.com/.

About SynlogicSynlogicis a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogics pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogics reproducible, target-specific drug design.Synlogicuses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. In addition to its clinical programs,Synlogichas a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease.Synlogichas also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout. For additional information visit http://www.synlogictx.com.

Story continues

Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," look forward, "estimate," "expect," "intend," on track, "plan," "predict" and similar expressions and their variants, as they relate toSynlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential ofSynlogicsapproach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approachSynlogicis taking to discover and develop novel therapeutics using synthetic biology; and the expected timing ofSynlogicsclinical trials of SYNB1618, SYNB1934, SYNB1353 and SYNB8802 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability ofSynlogicto protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" inSynlogicsfilings with theSEC. The forward-looking statements contained in this press release reflectSynlogicscurrent views with respect to future events.Synlogicanticipates that subsequent events and developments will cause its views to change. However, whileSynlogicmay elect to update these forward-looking statements in the future,Synlogicspecifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representingSynlogicsview as of any date subsequent to the date hereof.

Media Contact: Bill BerryBerry & Company Public Relations212-253-8881; bberry@berrypr.com

Investor Contact: Andrew FunderburkKendall Investor Relations617-914-0008; afunderburk@kendallir.com

The rest is here:
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease - Yahoo...

Bishop Garrison is vice president of government affairs and public policy at Paravision.

It is an iron law of progress that any innovation that benefits society also has the potential for harm. We saw it with the train and the automobile. We can already see it with genetic engineering. And now we are seeing it with artificial intelligence.

Every day brings a new report of how artificial intelligence is opening up new opportunities to detect disease and eliminate hunger, to understand the nature of the universe or to combat climate change. Yet darker uses are also emerging, including deepfakes, disinformation and autonomous weapons systems capable of using lethal force without human intervention.

We find ourselves on the doorstep of the next great societal challenge: harnessing the benefits of artificial intelligence while also ensuring it is used ethically and responsibly. It is our responsibility to establish processes and policies now to determine whether AI will be helpful or harmful in the future, and how we will protect against illicit or dangerous use. The problem is manifold: How do we ensure the private sector develops this technology ethically? What do AI ethics even entail? How do we keep social biases from being embedded in and amplified by AI?

These are not rhetorical questions. They represent issues of generational concern that require both great debate and an enormous amount of collaboration between the public and private sectors. Business leaders, academics and public servants must trust one another to smartly and thoughtfully devise these solutions together. No one group will have the answer, and no singular entity will know what is in the best interest of society regarding a technology with potential that rivals and perhaps exceeds any yet developed in human history. We must establish these tools of trust.

The stakes posed by this dilemma our need to get this right make it a formidable but not impossible task. During my time in government, I participated in initiatives that navigated a host of intricately detailed, politically charged and complex problems. We rethought the future of passenger screening at the Department of Homeland Security. We supported efforts to combat sexual assault and sexual harrassment within the ranks at the Department of Defense. And I led a group of dedicated career civil employees and uniformed service members to devise recommendations on countering extremist activity within the U.S. military. I learned that tackling these problems takes an investment in people and as well relationships built on trust.

These were all difficult tasks, on a professional and personal level. They were politically sensitive, divisive and required a whole-of-community approach to develop solutions that addressed the root causes of each problem. These issues are no less complicated, but also no less urgent. Given the projected long-term capabilities of AI, ensuring its ethical use is paramount to the safety and security of the global community.

If we do not come together now to address these challenges, the consequences will be devastating for our nation and societies worldwide. This will take governments at all levels working hand-in-hand with industry, academic, community and policy leaders in a lasting public-private partnership. Determining the proper oversight, regulatory framework and resourcing will be critical to create standards that result in the least harm and the most good while simultaneously ensuring that innovation and creativity in this arena do not become stifled or suffer a chilling effect.

Critics may object to the entire project on the grounds that ethical standards can only make U.S. AI companies less competitive. They may agree with former Google CEO Eric Schmidt, who once argued of face recognition, there is no U.S.-China contest; the United States has essentially conceded the race because of concerns over the average individuals privacy, and deep reservations about how this technology could be deployed.

While I greatly respect his experience and acumen, I disagree. The performance of U.S. face recognition companies in recent government benchmarks suggests that principled development is no obstacle to world-class AI performance. Perhaps more to the point, we have never been a country to run from the difficulties associated with solving hard problems or making generational breakthroughs. This is a time of challenge, a time of controversy, and it is our time to be measured.

Make no mistake: Devising a globally accepted set of AI principles and convincing private and public institutions to adopt it will be a heavy lift. But ignoring the challenge is not an option. If we want a future consonant with our values, we need to address this problem now, together, with every asset at our disposal.

Continue reading here:
The world needs an AI code of ethics - Protocol

BEIJING, Sept. 8, 2022 /PRNewswire/ -- YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biologics, announced that the Company received the approvals from the regulatory authorities of United Arab Emirates (UAE) and the Philippines to conduct Phase 2/3 clinical trials for its PIKA recombinant COVID-19 vaccine. The phase 2/3 clinical trials will evaluate the immunogenicity, efficacy and safety of PIKA COVID-19 vaccine as a booster injection among subjects who received 2 or more doses of inactivated COVID-19 vaccine. The trials are designed to be multi-country, multi-center studies with the enrollment of 9,300 participants in UAE, Philippines and Pakistan.

PIKA recombinant COVID-19 vaccine is a highly differentiated vaccine candidate with potential prophylactic and therapeutic benefits against COVID-19 infection. PIKA recombinant COVID-19 vaccine is composed of PIKA adjuvant and S protein antigen by using genetic engineering technology with appropriate stabilizer. The pre-clinical studies demonstrated that this vaccine candidate is capable of sustaining two year long of high levels of neutralizing antibodies against a wide range of the variants of the COVID-19 virus, including Omicron BA.2, BA.4/5.

Based on the Phase 1 interim results of PIKA COVID-19 vaccine in UAE, the participants who received the low dose of 5 ug per injection were able to achieve high levels of neutralizing antibodies against all currently prevalent SARS-CoV-2 variants, including Omicron BA.2, BA.4/5, both in the prime vaccination regimen and booster dose for subjects who completed 2 doses of inactivated vaccines. PIKA COVID-19 vaccine candidate demonstrated good safety profile in phase 1 study.

"The initiation of the phase 2/3 clinical trials in multi countries will accelerate the clinical development of PIKA recombinant COVID-19 vaccine candidate to a new level," said Mr Yi Zhang, the Chairman and the Project Leader at YishengBio. "PIKA recombinant COVID-19 vaccine candidate achieved high levels of immunogenicity and broad neutralizing antibodies in clinical trials against wide range of SARS-CoV-2 virus strains, including the most prevalent Omicron variant. This vaccine candidate has the potential to become a universal vaccine against the swiftly mutating SARS-CoV-2 virus worldwide. Equally important, our newly constructed manufacturing plant dedicated to the commercialization of PIKA recombinant COVID-19 vaccine was recently granted the drug manufacturing certificate by the China's National Medical Products Administration (NMPA). We are excited about the initiation of this clinical study and eager to bring this valuable and highly differentiated vaccine to the public health arena to help address critical unmet medical needs."

About PIKA Technology:

PIKA technology is an immuno-modulating technology platform based on synthetic biologic complex which is originated from Yishengbio's proprietary research and GMP manufacturing engineering process. Through TLR3, RIG-I and MDA-5 signaling pathways, PIKA molecule can induce prompt production of interferon, cytokines, chemokines and co-stimulatory factors. PIKA administration facilitates antigen cross-presentation by dendritic cells and augments CD4+ T-cell, CD8+ T-cell and natural killer-cell responses. When delivered with relevant antigen-based molecules, PIKA technology can be applied to the development of a new generation of antiviral vaccines, antiviral and anticancer therapeutics, offering a promising platform for the development of a wide variety of novel biologics to improve treatments that are currently available and address unmet medical needs.

About YishengBio:

YishengBio is a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generation of vaccines and therapeutic biologics for infectious diseases and cancer. YishengBio is expanding its business horizon with a global footprint across various countries, including China, United States, Singapore, the Philippines, Pakistan, the UAE and other countries. The Company has developed proprietary PIKA immunomodulating technology platform which augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. PIKA technology platform has empowered and nurtured a diverse and innovative pipeline of vaccines and therapeutic biologics with differentiated efficacy and safety profile to address the unmet medical needs in infectious disease and oncology.

YishengBio is one of the leading suppliers of human rabies vaccine in Chinese market and its development pipeline includes PIKA Rabies Vaccine, PIKA recombinant COVID-19 Vaccine, YS-HBV-001, YS-HBV-002 and YS-ON-001 targeting various prophylactic and therapeutic indications. YishengBio is headquartered in Beijing and has over 800 employees in China, U.S.A, Singapore and other countries in Asia. For more information on YishengBio, please visit http://www.yishengbio.com.

See the original post here:
YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine - PR Newswire APAC - PR...

DUBLIN--(BUSINESS WIRE)--The "Global Recombinant Cell Culture Supplements Market: Focus on Pricing Analysis, Product, Application, Expression System, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

The global recombinant cell culture supplements market was estimated at $308.6 million in 2021 and is expected to reach $1,188.6 million by 2032, growing at a CAGR value of 12.24% during the forecast period 2022-2032. The growth in the global recombinant cell culture supplements market is expected to be driven by the rising demand for cell culture supplements, increasing investment in life sciences research and development, as well as growing advantages of recombinant supplements over traditional animal-derived supplements.

Market Lifecycle Stage

The global recombinant cell culture market is increasing at a rapid pace. The growing need for animal-free supplements in cell culture applications is aiding the growth of the recombinant cell culture supplements market. Recombinant cell culture supplements play a crucial role in enhancing cell viability, maintaining a healthy culture, and customizing the cell culture in accordance with the needs of the individual.

Increasing demand for immunotherapy and stem cell and regenerative medicine research is one of the major opportunities in the recombinant cell culture supplements market. Several cell culture companies, and biopharmaceutical companies are working collaboratively on drug development and using recombinant cell culture supplements as a therapeutic means for applications in biological drugs. Furthermore, the market witnessed major mergers and acquisitions in the past four years. For instance, recently, in March 2022, Thermo Fisher Scientific Inc. acquired PeproTech, Inc., a company that specializes in the development and manufacturing of recombinant proteins, in a deal of $1.85 billion.

Impact

Many biopharmaceutical products are being developed by utilizing the cell culture technique. The study of cell physiology and biochemistry is made possible through laboratory cell culture, which also opens up research avenues that are challenging to pursue in vivo. Controlling variables such as the culture media, culture conditions, population density, and growth rate makes it simple to assess the effects of medications or other substances on cultured cells.

Additionally, it allows analyzing the function of various genes and offers enormous potential in the field of genetics. It enables the assessment of harmful and carcinogenic chemicals on cells in the fields of oncology and virology and the comprehension of how different medications, viruses, and physical or chemical carcinogens interact.

Furthermore, the recombinant cell culture has various applications, such as research on vaccines, stem cells, gene therapy, and genetic engineering, as well as the creation of protein therapies manufacturing of genetically edited proteins such as monoclonal antibodies, insulin, and hormones.

Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Market Segmentation

by Product

by Application

by Expression System

by Region

Demand - Drivers and Limitations

Following are the demand drivers for the global recombinant cell culture supplements market:

The market is expected to face some limitations too due to the following challenges:

Key Topics Covered:

1 Market Overview

2 Product, $ Mn, 2021-2032

3 Application, $Mn, 2021-2032

4 Expression System, $Mn, 2021-2032

5 Region, $Mn, 2021-2032

6 Competitive Landscape

7 Company Profiles

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/i5b3yo

Read more here:
Global Recombinant Cell Culture Supplements Market Report 2022: Increasing Demand for Recombinant Cell Culture Supplements Due to their Advantages...

Madrid.- Immunologist Carl Jun has started a revolution in medicine. He speaks of the resurrection himself like Lazarus, the man who died and was miraculously resurrected by Jesus Christ in the biblical account. June, born 69 years ago in Denver (United States), is the father of CAR-T treatment, a powerful strategy that includes Drawing blood from cancer patients, capturing their white blood cells, and re-engineering them in the laboratory to multiply their ability to kill cancer cells., Complete remission of blood tumorsleukaemia, lymphoma, and myelomaalready number in the hundreds.

The researcher remembers his first case, Bill Ludwig, a 65-year-old prison guard who died of leukemia in August 2010. He was a Catholic and he supported him immensely, recalls June, director of the Center for Cellular Immunotherapy at the University of Pennsylvania. The patient had a tumor of about three kilograms, but 20 days after a single injection of CAR-T cells, no sign of cancer was found. The challenge now is to reduce the exorbitant price of the treatment pharmaceutical companies charge more than 300,000 euros for each patient and make it work even in solid tumors such as the pancreas and brain.As June explains, passing through Madrid to deliver a speech at the Ramon Ares Foundation.

You use the word cure.

At 10 years old, yes. Our first two patients have already been free of leukemia for 10 years, so we can talk about a cure. They were cases like Lazaro. They thought they were about to die and both had the same reaction. When Bill Ludwig was told he no longer had leukemia, he bought a motorhome and traveled around the country with his wife, enjoying a vacation he had never had. The second patient, Doug Olson, is a scientist. When they told her that she no longer had leukemia, she bought a sailboat. Both of them thought that they were going to die and started a new life.

Compare these cases with Lazarus, the man who died and was resurrected by Jesus Christ in the Bible.

They thought they were going to die. Bill Ludwig had already paid for his funeral. Between 1997 and 2000, during the AIDS epidemic, I have seen something similar in medicine. Since there was no medicine, people who had AIDS died. Until effective drugs arrived. I saw it with AIDS and now I see it with these cancer patients who thought they were already dead and suddenly, rapidly, they were cured.

I think in 10 years the cost of CAR-T treatments will be a tenth of what they cost now

Do you know how many lives the CAR-T treatments have saved?

We know that more than 10,000 people in the world have received therapy. And many others are being treated with the experimental protocol. There are currently about a thousand clinical trials going on with CAR-T cells in the world.

-You were the promoter of the first authorized CAR-T therapy called kimariyah, In Spain, pharmaceutical company Novartis has fixed the price of Kymaria at 320,000 euros per patient. Do you think its a fair price? [Carl June reconoce un conflicto de intereses, ya que posee la propiedad intelectual de patentes licenciadas a Novartis]

-When we talk about fair price, it varies depending on the country. Its kind of awful, but Americas insurance companies are willing to pay $130,000 a year [cifra similar al cambio en euros] For anything that inspires you to live another year in health. The value of a person can be reduced to euros or dollars. And in the United States and Europe it is about $100,000 a year. They have observed that CAR-T cells offer a very long survival time. And theyve also studied the treatments that are used today: Other myeloma treatments, not CAR-Ts, cost a million dollars per patient and, on top of that, most die. In fact, CAR-T treatment is cheaper than it is now, even though they charge 300,000 euros. having said that, Its still expensive. The cost has to be reduced.

-How?

The most expensive part of CAR-T is the human work: Highly specialized scientists produce cells on a case-by-case basis, If robots could do this, it would be very cheap. This has already happened with many other new technologies, which eventually became cheaper to manufacture on a large scale. Computers were also very expensive earlier. What will happen to the CAR-T cell in 10 years? I am sure that instead of creating people in a procedure that requires two weeks, the hospital itself will have a machine in which the patients blood will be drawn and the CAR-T cells will come out on their own. I think in 10 years they will have to spend a tenth of their cost.

A Spanish public hospital, the Clinique de Barcelona, has developed its own CAR-T treatment against acute lymphoblastic leukemia and multiple myeloma. The price of these public CAR-Ts is 90,000 per patient, Novartis and other big pharma seem to be making a huge profit margin.

Well, the data so far shows that none of these big companies are making money from these cell therapies. Novartis makes a lot of profit out of the rest of the drugs it sells. The cost of producing a standard drug may be 5% of the direct selling price. In the case of CAR-T it is much higher. For example, they make much less money selling CAR-T cells than selling aspirin. Manuel Juan [jefe de Inmunologa del Hospital Clnic] He spent about three months with us learning how to make CAR-T cells and he is a great person. This has achieved a very efficient process, but has cost the pharmaceutical industry a lot. Different companies have to improve and make it cheaper, because thats how innovation and competition work. Unfortunately, it will probably take 10 years to fix this problem.

The most expensive part of CAR-T is human work: Very specialized scientists produce cells on a case-by-case basis. If it can be done by robots, it will be much cheaper.

-Novartis CEO, vas narasimhaniwon last year about 12 million euros, Does this salary make sense given the exorbitant cost of CAR-T treatments?

-Novartis has over 100,000 employees. These big pharmaceutical companies spend a lot of money on research and some of their drugs are life changing. You want to do research to develop new products, but you also dont want to make obscene profits. The average cost of new cancer drugs is more than $100,000 per year. CAR-T cells are the most expensive cancer treatment, but cell therapy for the treatment of sickle cell anemia and thalassemia has just been approved. I think they charge $2.3 million. It is a treatment for a fatal disease, but it is expensive as it requires a bone marrow transplant. And its far more difficult to do genetic engineering with stem cells [precursoras de las clulas de la sangre en la mdula sea], It is the most expensive treatment in the United States right now. Sickle cell anemia kills you. It is the most common fatal genetic disease and occurs mainly in black people who do not have health insurance. So now we have a way to treat it, but of course nobody has $2.3 million.

Drugs dont work if people cant afford them.

-accurate. Technology is making it possible to do things that have never been done before, such as cell engineering. Its expensive, but it works. The question is how to make it fair. Ive been to Costa Rica three times and were going to start a trial to see if we can develop this technology in a middle-income country. Right now there are no trials with CAR-T cells in Central or South America, only in Europe, the United States, China and Japan.

A decade ago, you said in an interview That all research on CAR-T treatment was being done in universities. Now it is the companies that take advantage.

Yes, this is a common problem in the United States and Europe. Citizens pay with their taxes to educational centers for the development of these treatments, and then they pay again to receive therapy.

Citizens pay twice for the same medicine.

Yes, this is a problem that should be solved with policies. Science is top notch. Research is now taking place in both industry and academia. Ten years ago research was academic only. Pharmaceutical companies now make more money than the US National Cancer Institute, which doesnt mean they do the most innovative research.

There are about 300 types of cancer and each one has pain in the heel which makes it vulnerable

CAR-T therapies against leukemia, lymphoma and myeloma have been approved in many countries. What about solid tumors, such as tumors of the pancreas, brain, or lung?

-There are experimental trials with all of these, but none of these treatments are authorized. We need more research. Pancreatic cancer and brain cancer are two of the worst and are already progressing. We now have an exciting trial at the University of Pennsylvania, in which we are combining an oncolytic virusa virus modified to infect tumor cellsand CAR-T cells. Were Doing It With Ramon Alemanni [investigador del Instituto Cataln de Oncologa], which is in Barcelona. So far we have treated only one patient, but it is very exciting. This is for pancreatic cancer and ovarian cancer. I think were going to need these kinds of combinations to deal with solid tumours. It is far more difficult for the immune system to completely eliminate a solid tumor than it is for leukemia. There have been about a thousand trials of CAR-T now, its being tested on any cancer you can think of.

Do you think that in 10 years there will be effective CAR-T cells against solid tumors?

There are about 300 types of cancer and each one causes heel pain which makes it debilitating. unfortunately, We are not going to have a single cure for all cancers. I think what we will have is, for example, something that only works against ovarian cancer, that works against breast cancer, or against leukemia. For leukemia you only need a single infusion of CAR-T cells and thats it. In solid tumors it would be much more complicated. In a laboratory dish, CAR-T cells kill pancreatic cancer, but in people solid tumors have a wall around them that prevents CAR-T cells from penetrating. This blood is not present in the tumor.

Manuel Ansede. By

EL PAS, SL

Read this article:
Cancer: "I See Patients Who Thought They Were Already Dead And Suddenly, They Are Cured", Says Father Of A Revolutionary Treatment - Nation...